Power secures $11.9M in funding to revolutionize clinical trials, led by Kin, Contrary, and Footwork. Founded in 2021, Power aims to simplify trial recruitment and diversify participant pools. With over 600,000 patients using the platform in the past year, participation and efficiency are growing. The funding enables expansion to support researchers and create a more equitable trial ecosystem, advancing Power’s mission to democratize access and accelerate life-saving medical research.
Power, a company revolutionizing the clinical trial landscape, has secured $11.9M in Series A funding led by Kin, Contrary, and Footwork.
This funding will further Power’s mission to democratize clinical trial access, diversify participant pools, and expedite crucial medical research.
Revolutionizing Clinical Trial Participation
Established in 2021 by Brandon Li and Michael Gill, Power aims to simplify and make transparent the often complex process of clinical trial recruitment. Through a patient-centered platform, Power empowers users to:
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
– Easily find relevant trials based on individual needs and criteria.
– Access understandable information about the trial process and connect directly with researchers.
– Engage in trials confidently, supported from enrollment to completion.
Significant Growth and Impact
In the past year alone, over 600,000 patients have utilized Power to discover clinical trials, with a 20% monthly increase in study team participation on the platform. This growth enhances efficiency and expedites enrollment, while also fostering diversity by attracting participants more representative of the US population.
Expansion Plans
With the latest funding infusion, Power is poised to expand its platform capabilities, provide enhanced support to researchers, and cultivate a more equitable clinical trial ecosystem.
